TXRX's new East End Space will allow them to provide prototyping and manufacturing services to more innovators. Courtesy of TXRX

With grants and public funds secured, Houston-based TXRX Labs as one last round of fundraising to acquire before it's ready to head full-speed ahead into its new location.

TXRX launched a $85,000 fundraising campaign to help get the organization where it needs to be before it moves into its 60,000-square-foot space in the East End Maker Hub in spring or summer of next year. The organization, along with its sister nonprofit, Urban Partnership Community Development Corp., has been selected by the city of Houston for an $18 million award and by the federal government for a $5 million innovation grant.

"In the last two weeks, we were getting close to finalizing funding for the building and came up short," says Lauren Caldarera, development director at TXRX. "We wanted to reach out to our membership at TXRX and the broader Houston community to help see if people will help support this unique offering for Houston."

In order to receive those grants, TXRX needs to submit design materials — a process that they budget to cost $325,000. (TXRX has already procured $240,000.) An anonymous donor agreed to match donations, and the organization has until the end of May to raise. Anyone can donate online.

TXRX is focused on bringing back Houston's East End as a manufacturing hub. As manufacturing jobs left the second, third, and fifth wards, it's created a need for skilled labor, middle class jobs, says Roland von Kurnatowski, executive director of TXRX.

"We're looking to bring together innovative companies in the physical innovation space into the East End and creating these middle class jobs," says von Kurnatowski. "It's a modern approach to combating economic inequalities instead of providing handouts."

TXRX is already making a dent in their mission with their smaller space. The organization has over 400 members and incubates 20 or so companies. The new space will allow TXRX to incubate almost twice that amount, work with 75 companies who need prototyping and manufacturing services, and grow their classes and educational offerings.

"Having this space is critical as Houston moves forward in creating an innovation ecosystem," Caldarera says. "We need a space for people to develop their physical prototypes, have engineers and other experts to coach and mentor them, and create more startups and innovators here."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.